First-Line Combination Therapy for EGFR-Mutated NSCLC

Osimertinib is the preferred first-line treatment for most patients with non–small-cell lung cancer (NSCLC) who harbor common EGFR mutations. Unfortunately, despite initial deep response, many patients experience progressive disease in less than 1.5 years. Several drug combinations, including osimertinib plus pemetrexed chemotherapy, have shown promise compared with osimertinib alone.

The phase 3 industry-supported MARIPOSA study compared amivantamab plus lazertinib to osimertinib alone in patients with previously untreated, locally advanced or metastatic NSCLC with EGFR exon 19 deletion or L858R substitution mutations. Amivantamab is a bispecific antibody targeting EGFR and MET; lazertinib is a third-generation, central nervous system–penet…